Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alchemia Of Australia Finally Set To File For Synthetic Drug Generic

This article was originally published in PharmAsia News

Executive Summary

Australia's Alchemia is looking for marketing partners now that it has overcome a three-year delay and filed for U.S. approval of its synthetic anti-clotting generic of GlaxoSmithKline's Arixtra (fondaparinux). Alchemia blamed its delay beyond the original 2006 filing target on the complexities involved in synthesizing the drug. The company expects FDA approval and marketing in the second half of this year, with Dr. Reddy's Laboratories already chosen to market the drug in India. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts